Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis

Chiara Fenoglio, Claudia Cantoni, Milena De Riz, Elisa Ridolfi, Francesca Cortini, Maria Serpente, Chiara Villa, Cristoforo Comi, Francesco Monaco, Luisa Mellesi, Stefano Valzelli, Nereo Bresolin, Daniela Galimberti, Elio Scarpini

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

MicroRNA (miRNA)-mediate RNA interference has been identified as a novel mechanism that regulates protein expression. It is recognised that miRNAs play essential roles in the immune system and for correct function in the brain. Moreover, it is now clear that abnormal miRNA expression is a common feature of several diseases involving the immune system including multiple sclerosis (MS). Expression analysis for miR-21, miR-146a and -b, miR-150, miR-155 was carried out in peripheral mononuclear cells (PBMC) from a cohort of 29 MS patients and 19 controls. Subsequently, a case control study for miR-146 rs2910164 variant was performed in an overall population of 346 MS cases and 339 controls. A statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls (1.44 ± 0.13 vs 0.79 ± 0.06, P=0.036; 1.50 ± 0.12 vs 0.84 ± 0.08, P=0.039; 1.54 ± 0.15 vs 0.72 ± 0.08, P=0.001 respectively). On the contrary, no differences were found in the expression levels of both miR-150 and miR-155 in patients as compared with controls (P>0.05). The genetic association study failed to find any differences in the frequencies of rs2910164 between patients and controls. miRNA dysregulation may contribute to the pathogenesis of MS and highlights the possibility to define different disease entities with specific miRNAs profile.

Original languageEnglish
Pages (from-to)9-12
Number of pages4
JournalNeuroscience Letters
Volume504
Issue number1
DOIs
Publication statusPublished - Oct 17 2011

Fingerprint

MicroRNAs
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Immune System Diseases
Genetic Association Studies
RNA Interference
Case-Control Studies
Immune System
Brain
Population
Proteins

Keywords

  • CD4+
  • Gene expression
  • Immune system
  • MiRNA
  • Multiple sclerosis
  • Risk factor

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. / Fenoglio, Chiara; Cantoni, Claudia; De Riz, Milena; Ridolfi, Elisa; Cortini, Francesca; Serpente, Maria; Villa, Chiara; Comi, Cristoforo; Monaco, Francesco; Mellesi, Luisa; Valzelli, Stefano; Bresolin, Nereo; Galimberti, Daniela; Scarpini, Elio.

In: Neuroscience Letters, Vol. 504, No. 1, 17.10.2011, p. 9-12.

Research output: Contribution to journalArticle

Fenoglio, Chiara ; Cantoni, Claudia ; De Riz, Milena ; Ridolfi, Elisa ; Cortini, Francesca ; Serpente, Maria ; Villa, Chiara ; Comi, Cristoforo ; Monaco, Francesco ; Mellesi, Luisa ; Valzelli, Stefano ; Bresolin, Nereo ; Galimberti, Daniela ; Scarpini, Elio. / Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis. In: Neuroscience Letters. 2011 ; Vol. 504, No. 1. pp. 9-12.
@article{330c65e50800438797af1aa423278da6,
title = "Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis",
abstract = "MicroRNA (miRNA)-mediate RNA interference has been identified as a novel mechanism that regulates protein expression. It is recognised that miRNAs play essential roles in the immune system and for correct function in the brain. Moreover, it is now clear that abnormal miRNA expression is a common feature of several diseases involving the immune system including multiple sclerosis (MS). Expression analysis for miR-21, miR-146a and -b, miR-150, miR-155 was carried out in peripheral mononuclear cells (PBMC) from a cohort of 29 MS patients and 19 controls. Subsequently, a case control study for miR-146 rs2910164 variant was performed in an overall population of 346 MS cases and 339 controls. A statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls (1.44 ± 0.13 vs 0.79 ± 0.06, P=0.036; 1.50 ± 0.12 vs 0.84 ± 0.08, P=0.039; 1.54 ± 0.15 vs 0.72 ± 0.08, P=0.001 respectively). On the contrary, no differences were found in the expression levels of both miR-150 and miR-155 in patients as compared with controls (P>0.05). The genetic association study failed to find any differences in the frequencies of rs2910164 between patients and controls. miRNA dysregulation may contribute to the pathogenesis of MS and highlights the possibility to define different disease entities with specific miRNAs profile.",
keywords = "CD4+, Gene expression, Immune system, MiRNA, Multiple sclerosis, Risk factor",
author = "Chiara Fenoglio and Claudia Cantoni and {De Riz}, Milena and Elisa Ridolfi and Francesca Cortini and Maria Serpente and Chiara Villa and Cristoforo Comi and Francesco Monaco and Luisa Mellesi and Stefano Valzelli and Nereo Bresolin and Daniela Galimberti and Elio Scarpini",
year = "2011",
month = "10",
day = "17",
doi = "10.1016/j.neulet.2011.08.021",
language = "English",
volume = "504",
pages = "9--12",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis

AU - Fenoglio, Chiara

AU - Cantoni, Claudia

AU - De Riz, Milena

AU - Ridolfi, Elisa

AU - Cortini, Francesca

AU - Serpente, Maria

AU - Villa, Chiara

AU - Comi, Cristoforo

AU - Monaco, Francesco

AU - Mellesi, Luisa

AU - Valzelli, Stefano

AU - Bresolin, Nereo

AU - Galimberti, Daniela

AU - Scarpini, Elio

PY - 2011/10/17

Y1 - 2011/10/17

N2 - MicroRNA (miRNA)-mediate RNA interference has been identified as a novel mechanism that regulates protein expression. It is recognised that miRNAs play essential roles in the immune system and for correct function in the brain. Moreover, it is now clear that abnormal miRNA expression is a common feature of several diseases involving the immune system including multiple sclerosis (MS). Expression analysis for miR-21, miR-146a and -b, miR-150, miR-155 was carried out in peripheral mononuclear cells (PBMC) from a cohort of 29 MS patients and 19 controls. Subsequently, a case control study for miR-146 rs2910164 variant was performed in an overall population of 346 MS cases and 339 controls. A statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls (1.44 ± 0.13 vs 0.79 ± 0.06, P=0.036; 1.50 ± 0.12 vs 0.84 ± 0.08, P=0.039; 1.54 ± 0.15 vs 0.72 ± 0.08, P=0.001 respectively). On the contrary, no differences were found in the expression levels of both miR-150 and miR-155 in patients as compared with controls (P>0.05). The genetic association study failed to find any differences in the frequencies of rs2910164 between patients and controls. miRNA dysregulation may contribute to the pathogenesis of MS and highlights the possibility to define different disease entities with specific miRNAs profile.

AB - MicroRNA (miRNA)-mediate RNA interference has been identified as a novel mechanism that regulates protein expression. It is recognised that miRNAs play essential roles in the immune system and for correct function in the brain. Moreover, it is now clear that abnormal miRNA expression is a common feature of several diseases involving the immune system including multiple sclerosis (MS). Expression analysis for miR-21, miR-146a and -b, miR-150, miR-155 was carried out in peripheral mononuclear cells (PBMC) from a cohort of 29 MS patients and 19 controls. Subsequently, a case control study for miR-146 rs2910164 variant was performed in an overall population of 346 MS cases and 339 controls. A statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls (1.44 ± 0.13 vs 0.79 ± 0.06, P=0.036; 1.50 ± 0.12 vs 0.84 ± 0.08, P=0.039; 1.54 ± 0.15 vs 0.72 ± 0.08, P=0.001 respectively). On the contrary, no differences were found in the expression levels of both miR-150 and miR-155 in patients as compared with controls (P>0.05). The genetic association study failed to find any differences in the frequencies of rs2910164 between patients and controls. miRNA dysregulation may contribute to the pathogenesis of MS and highlights the possibility to define different disease entities with specific miRNAs profile.

KW - CD4+

KW - Gene expression

KW - Immune system

KW - MiRNA

KW - Multiple sclerosis

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=80053459864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053459864&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2011.08.021

DO - 10.1016/j.neulet.2011.08.021

M3 - Article

C2 - 21875645

AN - SCOPUS:80053459864

VL - 504

SP - 9

EP - 12

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 1

ER -